Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin
Galderma announced that Restylane Shaype has been approved in the European Union (EU) under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.
Powered by Galderma’s new NASHA HD technology, Restylane Shaype is the firmest HA injectable gel available among market leaders in the facial filler market, with the highest G’ (measure of firmness) of the Restylane range. As the first-and-only HA dermal filler specifically designed to allow aesthetic injectors to build and shape on the lower angles of the face, it provides greater projection with lower injection volumes. Underpinning the Restylane range is a minimally modified HA gel that closely resembles naturally occurring HA, requires less product than other HA gels, and can be readily reversed, offering both performance and reassurance.
In a pivotal 12-month study, 83% of people treated with Restylane Shaype showed improved structure and definition at three months (66% at 12 months). 84% of patients would agree to be treated with Restylane Shaype again, and up to 97% of patients would recommend treatment with Restylane Shaype to a friend. Restylane Shaype injections are administered with a new, next-generation syringe to enhance precision and control through its ergonomic design and optimized syringe-needle connection.
To support consistent, individualized use of Restylane Shaype in clinical practice, Galderma has developed the Shayping Technique. The technique combines Galderma’s Assessment, Anatomy, Range, and Treatment (AART) methodology and the Facial Assessment Scale (FAS), enabling healthcare professionals to systematically evaluate lower face anatomy and facial balance, helping to identify individual patient priorities and treatment goals. This assessment-led approach supports a broader understanding of lower face structure and is aligned with ongoing investigations of Restylane Shaype in areas such as the jawline.
The distinctive bone-mimicking effect of Restylane Shaype reinforces how the Restylane HA treatment range is well-placed to address evolving aesthetic needs across all life stages, including aesthetic changes associated with medication-driven weight loss and menopause, which can affect bone density, structural support, and skin health.
With over 30 years of innovation and more than 77 million treatments administered worldwide, the Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs. As patient expectations shift toward more effortless, always-on rejuvenation, Galderma’s ‘Wake Up To Restylane’ campaign positions Restylane as an everyday natural beauty ally for the face and other areas of the body, highlighting Galderma’s commitment to meeting emerging needs. Focused on the growing desire for natural, authentic results, the campaign underscores Restylane’s ability to deliver personalized outcomes that go beyond volumizing, helping people feel confident in their skin.
